Johnson & Johnson has announced positive topline results from the phase 3 MonumenTAL‑6 study, which evaluated TECVAYLI and TALVEY as a dual antigen regimen targeting BCMA and GPRC5D in adults with relapsed or refractory multiple myeloma. The company reported statistically significant improvements in progression‑free survival and overall survival for both investigational regimens. TECVAYLI plus TALVEY delivered the strongest benefit, reducing the risk of disease progression or death by 89% and the risk of death by 62%. Yusri Elsayed, Global Therapeutic Area Head, Oncology, Johnson & Johnson, explained: “At Johnson & Johnson, we have intentionally built a multiple myeloma portfolio that spans biological targets, mechanisms, modalities and lines of therapy, giving physicians the flexibility to use our therapies across a diverse patient population and throughout the patient journey.” He continued: “These findings further reinforce immunotherapy as a cornerstone of multiple myeloma care and strengthen the growing body of evidence supporting our leadership in this space.